Amphastar Pharmaceuticals (AMPH) Projected to Release Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of $0.66 per share and revenue of $179.9210 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.28). Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. The business had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. On average, analysts expect Amphastar Pharmaceuticals to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $19.90 on Wednesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.82 and a current ratio of 3.85. Amphastar Pharmaceuticals has a 52 week low of $16.65 and a 52 week high of $31.26. The stock has a market capitalization of $877.39 million, a P/E ratio of 11.99, a price-to-earnings-growth ratio of 4.27 and a beta of 0.89. The stock has a fifty day moving average of $19.59 and a 200-day moving average of $21.48.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on AMPH shares. Piper Sandler reiterated a “neutral” rating and issued a $21.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 11th. Wells Fargo & Company restated an “equal weight” rating and issued a $19.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research report on Thursday, May 14th. Zacks Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, July 8th. Finally, Barclays cut their price objective on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating on the stock in a report on Wednesday, June 3rd. Six research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $22.00.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its holdings in Amphastar Pharmaceuticals by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,799,685 shares of the company’s stock worth $48,196,000 after acquiring an additional 44,020 shares during the last quarter. State Street Corp raised its stake in shares of Amphastar Pharmaceuticals by 2.1% during the fourth quarter. State Street Corp now owns 1,531,786 shares of the company’s stock valued at $41,021,000 after acquiring an additional 31,044 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 3.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock worth $37,344,000 after purchasing an additional 40,536 shares during the period. Marshall Wace LLP grew its stake in shares of Amphastar Pharmaceuticals by 41.6% in the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock worth $33,134,000 after purchasing an additional 363,216 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Amphastar Pharmaceuticals by 12.7% in the third quarter. Millennium Management LLC now owns 697,765 shares of the company’s stock worth $18,595,000 after purchasing an additional 78,781 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.